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Abstract  
Context: COVID-19 is a new pandemic in the world and data in the various aspect of this disease are evolving. 
In this review, the authors tried to cover different aspects of clinical manifestations and the natural course of 
the disease. 
Evidence acquisition: For data gathering, the authors searched through MEDLINE, Cochrane library, google 
scholar and Scopus. The key phrases for search were "clinical presentation of COVID-19", "clinical features of 
COVID-19", "natural course of COVID-19", "neurologic manifestation of COVID-19", "cardiovascular 
manifestation of COVID-19" and "gastrointestinal manifestation of COVID-19".    
Results: After screening of titles and abstracts, the authors finally enrolled 55 articles. Then the full texts of 
the selected articles were read carefully to determine eligibility and extracting relevant information. 
Conclusion: The most common presentations of COVID-19 patients were fever, non-producing cough and 
dyspnea but a considerable amount of patients may seek heath care without these complaints. Asymptomatic 
patients and patients with only gastrointestinal and neurologic symptoms remain a significant challenge for 
medical practitioners. 
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CONTEXT
Primary information about COVID-19 was 
provided back in December 2019 when physicians 
in Wuhan, China, encountered patients with 
manifestations of this viral pneumonia for the first 
time (1). The highly contagious nature of this new 
disease, which helps it spread easily in the society, 
has attracted the attention of regional and 
international health related organizations. On 11 
March 2020 the World Health Organization (WHO) 
declared the disease as a worldwide problem and 
pandemic (2). By 10 April 2020 more than 1.5 
million people in the world were affected by this 
virus and COVID-19 was reported in most 
countries (3, 4). The clinical manifestations of 
COVID-19 make up a spectrum; at one extreme 
there are asymptomatic cases, and at the other, 
there are patients with severe respiratory distress 
syndrome (SARS-CoV-2) and shock who finally die 
(4-6). Total fatality rate differs around the world, 
ranging from 3.8% in China to 9% in Italy (2, 7, 8). The 
center for disease control and prevention (CDC) of 
China categorized the disease manifestations as 
mild and moderate (none or mild pneumonia), 
severe (dyspnea, respiratory rate (RR) ≥30, oxygen 
saturation (Spo2) ≤93%, Pao2/Fio2 ≤300 or 
pulmonary infiltration ≥50% in 24-48 hours) and 
critical (respiratory compromise, septic shock, 
multiple organ failure) (9, 10). In this review, the 
authors tried to cover different aspects of clinical 
manifestations and the natural course of the disease. 
EVIDENCE ACQUISITION 
To extract evidence, the authors searched for 
articles in Medline, Google Scholar, Cochrane data 
base for systematic reviews and Scopus. The key 
words were "clinical presentation of COVID-19", 
"clinical features of COVID-19", "natural course of 
COVID-19", "neurologic manifestation of COVID-
19", "cardiovascular manifestation of COVID-19" 
and "gastrointestinal manifestation of COVID-19". 
All types of articles, such as reviews, originals, 
letters, and etc., were included in the study. Online 
articles that were not peer-reviewed and accepted 
to a specific journal were excluded from the study. 
In the next stage, the researchers read titles and 
abstracts of search engine results and selected 
related articles to probe their main text for more 
details in. Finally, articles that consisted of 
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confirmed cases of COVID-19 based on reverse 
transcription polymerase chain reaction (RT-PCR) 
test and included data related to the main research 
subject were chosen for data extraction. 
RESULS 
General Considerations 
In the early stages of disease outbreak, most 
patients were related to a seafood market; but 
later, a huge number of patients visited medical 
facilities with symptoms and signs of COVID-19 and 
positive RT-PCR in china and all over the world. 
These new surges of the disease indicated that the 
source of the prevalence should be human to 
human transmission of the disease (2, 6). 
Respiratory droplets are the main source of direct 
infection transmission in communities but virus 
could survive on different surfaces for considerable 
times and transfer to the others indirectly (2). 
Studies have proved virus shedding in feces and 
now fecal-oral transmission is deemed a potential 
source of infection. Currently, there is no evidence 
suggesting airborne transmission of COVID-19 (2). 
The disease is more common in males and also 
critical cases are more frequent in males (67% vs 
33%) (11-13). Incubation period of this disease is 
about 5.1 days (2 to 14 days) and the mean age of 
the patients is 59 years old (36 hours to 92 years) 
(2, 12-14). The most prevalent symptoms and signs are 
fever and chill, cough, dyspnea, fatigue or myalgia, 
sore throat, headache, diarrhea, nausea and 
vomiting, sputum production, rhinorrhea and 
hemoptysis, respectively (15-22). Hypertension, 
diabetes, chronic respiratory disease and 
cardiovascular disease are comorbidities that were 
present in about 50% of the patients (9, 15, 16). Age 
≥60 years, high sequential organ failure 
assessment (SOFA) Score on admission, male 
gender, d-dimer ≥1 micromol/L, and presence of 
comorbid diseases and malignancies are 
prognostic factors for poor outcome among 
patients with COVID-19 (6, 17-19). 
Constitutional symptoms 
Fever is the most prevalent constitutional 
symptom reported in various studies. The other 
symptoms in this category are Myalgia, fatigue, 
weakness (20-25). 
Respiratory tract manifestations 
Respiratory manifestations include some features 
of upper respiratory tract involvement such as: 
sore throat, rhinorrhea and nasal congestion but in 
more server cases patients may complain of lower 
respiratory tract involvements that include cough, 
chest tightness, hemoptysis, dyspnea and severe 
air hunger that could finally lead to refractory 
pneumonia and SARS (18, 21-25). Mo et al. defined 
refractory pneumonia in COVID-19 patients as 
continuing and unrevealing symptoms and hospital 
stay of more than 10 days. They showed that these 
patients were older and male and had more 
comorbidity. In laboratory evaluation these 
patients had a higher level of neutrophils in 
complete blood count (CBC), Lactate 
dehydrogenase (LDH), C-reactive protein (CRP), 
ferritin, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and lower level of albumin 
and platelets. Bilateral lung involvements were 
more common in these patients (18). In 80.9% of 
patients the clinical course of the disease is mild to 
moderate and consists of varying degrees of 
constitutional symptoms plus some of the 
respiratory tract manifestations (7). In 13.8% of 
patients the disease progresses to the severe form 
with prominent respiratory symptom such as: 
severe dyspnea, RR ≥30, Spo2 ≤93% and 
Pao2/Fio2 <300 and involvement of more than 
50% of lung parenchyma in imaging modalities. 
Unfortunately, in about 5% of cases, disease 
progresses to the critical stage, which presents 
with multi-organ dysfunction, septic shock and 
respiratory compromise (6, 7). Based on the results 
of Pao2/Fio2, acute respiratory distress syndrome 
(ARDS) is categorized as mild, moderate and severe 
(>100, 100-200, 200-300 respectively). In critical 
forms, patients’ mortality rate increases to 49% (6). 
Gastrointestinal manifestations 
Gastrointestinal (GI) symptoms could be the only 
manifestation in COVID-19 patients (26-29). There 
are some reasons for manifestation of 
gastrointestinal symptoms in these patients: First, 
the virus invades human cells via angiotensin 
converting enzyme 2 (ACE2) receptors and these 
receptors exist in the liver and intestine. Second, 
inflammatory response to the virus may cause 
some intestinal damage and consequently make 
changes to bowel flora, which could be a possible 
explanation for GI symptoms (28, 29). GI features of 
COVID-19 include anorexia, nausea and vomiting, 
diarrhea, GI bleeding and abdominal pain. 
Prevalence of GI symptoms varied in different in 
studies, ranging from 3% in primary studies to 
79% in latter ones (29). In the study conducted by 
Zhou et al., there was no correlation between GI 
symptoms and disease severity (27); but in the other 
studies performed by Jin et al. (26) and Pan et al (28), 
GI symptoms were more common in severe and 
critical cases. Alimentary tract symptoms may be 
the first presenting problem or may evolve during 
admission and disease progression. GI symptoms, 
mostly anorexia and abdominal pain, were more 
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prevalent in intensive care unit (ICU) admitted 
patients (29). Virus could be shed in the feces and 
probably infect the others via fecal-oral 
transmission. Studies show that fecal shedding may 
commence 2-5 days after positive respiratory tests 
and will continue to be positive a few days after 
negative respiratory test (26, 29). Family clustering of 
disease increased in patients with GI symptoms (26). 
Liver involvement and rise in AST and ALT were 
more common in COVID-19 patients with GI 
symptoms (26, 28, 29). 
Cardiovascular manifestations 
Cardiovascular diseases are common 
comorbidities in COVID-19 patients (30-36). ICU 
admission rates and severe forms of disease are 
more frequent in patients with cardiovascular 
diseases such as hypertension and coronary artery 
disease. Similarly, risk of death due to COVID-19 is 
higher in these patients (33, 35). In some cases of 
COVID-19, cardiac complaints such as palpitation 
and chest discomfort were the first reasons that 
brought the patients to a clinic (32). Currently, there 
are a few hypotheses to explain the cardiac effects 
of COVID-19 on infected patients. One of them is 
direct cytotoxic effect of virus, secondary to 
entrance to cardiac cells after binding to ACE2. 
Binding of the virus to ACE2 leads to down 
regulation of this receptor, which could generate 
imbalance in renin angiotensin system and 
increase in the level of angiotensin 2. Increased 
level of angiotensin 2 is responsible for cardiac 
hypertrophy, diastolic dysfunction, and cardiac 
fibrosis (36). In addition, hypoxia generated as a 
result of pulmonary involvement and ARDS may 
also lead to cardiac injury (31, 33). Inflammatory 
cytokines released in the circulation due to cellular 
reaction to virus such as: CRP, IL-6, TNF- α and IFNᵧ 
are another possible mechanism of cardiac injuries 
(35). Elevation of ST segment and chest discomfort 
as well as decline in ejection fraction have been 
reported in COVID-19 patients with normal 
coronary vessels in angiography, which improved 
with corticosteroid therapy. This this may indicate 
to inflammatory nature of the problem (33). 
Electrolyte imbalance and adverse effects of 
antiviral drugs may lead to some degree of cardiac 
injury (31). Cardiac injury, new electrocardiogram 
(ECG) and echocardiographic changes have been 
reported in 22% of ICU admitted patients but the 
overall rate of these involvements among all 
COVID-19 patients was 7.2% (33). Elevated level of 
cardiac troponin I or T (cTnI, cTnT), as a sign of 
cardiac injury, and myocarditis have been reported 
in several studies (31, 34). A considerable rise in cTnI 
has been reported in 8 to 12 % of COVID-19 
patients (31). A high level of these markers 
correlated with more severe forms of COVID-19 
infection and higher mortality rate of the patients 
(30-36). Mortality rate in patients with elevated level 
of cTnT and no history of cardiac disease was 
higher than patients with normal level of cTnT and 
previous history of cardiovascular disease (34). 
Incidence of heart failure was 52% in patients that 
eventually died of COVID-19 infection but only 
12% of the survivors showed signs of heart failure. 
Tachyarrhythmias and bradyarrhythmias were 
observed in these patients and were more 
prevalent in ICU admitted (44.4%) patients 
compared to non-ICU patients (8.9%) (31). 
Genitourinary manifestations 
Renal function abnormalities and acute kidney 
injury are common in patients with COVID-19. The 
mechanism of renal injury may be related to sepsis 
mediated inflammatory response or the direct 
toxic effect of virus on renal cells via ACE2, which 
exists on nephrocytes. The virus was also extracted 
from urine sample of the infected patients (30, 37).  In 
a study that was conducted on 710 hospital-
admitted patients, rate of proteinuria and 
hematuria was 44%; and 27% of these patients had 
hematuria on admission. In evaluation of renal 
function tests, rises in serum creatinine and blood 
urea nitrogen have been reported in 15.5% and 
14.4% of the patients, respectively. In radiologic 
evaluation of kidneys, inflammation and edema 
have been reported (37). Acute kidney injury is more 
prevalent in ICU admitted patients with COVID-19 
and is an independent risk factor of death (30, 37). 
Orchitis has been reported in the previous 
coronavirus outbreaks and there is also the 
possibility of testis inflammation in COVID-19, but 
currently, there are not enough data in this regard. 
ACE2 is also presented on the surface of leydig cells 
in the testes (30). 
Laboratory findings 
There are a few laboratory abnormalities in 
hospital admitted COVID-19 patients and some of 
these derangements have prognostic properties. 
Leukopenia was one of the most reported 
abnormalities in the studies (12, 14, 16-19, 22). The other 
common laboratory abnormalities included 
increase in AST, ALT, CRP, LDH, erythrocyte 
sedimentation rate (ESR), d-dimer and 
prothrombin time (PT) (14). Pro-inflammatory 
cytokines including ferritin, IL2, IL7, IL10, GSCF, 
IP10, MCP1, MIP1A and TNF-ɑ levels are high in 
COVID-19 patients and these levels significantly 
increase in severe cases and ICU admitted patients 
(17). Procalcitonin is usually normal on admission, 
but in some cases it increases during 
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hospitalization, which may be due to possible super 
infections (12, 14). In the severe form of this disease, 
platelet counts and albumin level may decrease 
significantly. Patients with refractory pneumonia 
had higher levels of neutrophils, AST, CRP and 
lower levels of albumin (18). Abnormal renal 
function test and increase in cardiac troponin may 
be found in some COVID-19 patients and these 
abnormalities also are correlated with poor 
prognosis in these patients (31, 37). In general, 
existence of laboratory derangements and degree 
of severity are more common in severe and critical 
forms of the disease.  
Neurologic manifestations 
SARS-CoV-2 may enter the brain via the 
hematogenous route or direct invasion through 
cribriform palate, which may explain loss of the 
sense of smell in some COVID-19 patients. Anosmia 
may occur in some COVID-19 patients in the first 
days of infection. ACE2, a receptor for SARS-CoV-2, 
is present in the nervous system and brain 
autopsies have shown some degree of neuronal 
destruction. These may explain the possible 
neurologic manifestations of COVID-19 (38, 39). 
Central nervous system (CNS) invasion and causing 
encephalitis have been reported in other members 
of the coronavirus family and SARS-CoV-2 may 
have similar abilities. In previous outbreaks of 
coronaviruses, these viruses were detected in the 
cerebrospinal fluid of infected patients. Neurologic 
manifestations of COVID-19 could be classified into 
CNS and peripheral nervous system (PNS) 
manifestations. CNS presentations include 
headache, dizziness, seizure, decreased level of 
consciousness, cerebrovascular accident and PNS 
involvements are decrease taste and smell 
sensation and neuralgia (40). In a research by Mao et 
al. on 217 COVID-19 patients, 36.4% had 
neurologic symptoms. The most prevalent CNS and 
PNS symptoms were dizziness and anosmia, 
respectively. CNS complications were more 
common in the severe form of COVID-19 infection 
and such cases had lower levels of platelets and 
lymphocytes and a higher level of blood urea 
nitrogen in comparison to patients without CNS 
symptoms. With regards to PNS involvement, there 
were no significant laboratory discrepancies 
between patients with and without PNS 
manifestations. They also showed that patients 
may come to healthcare facilities only with 
neurologic manifestations. One of the important 
issues in COVID-19 patients with neurologic 
dysfunction is difficulty to exclude hypoxia, 
metabolic and electrolyte abnormalities as 
potential causes of these disorders (41).  
Special populations 
 Pregnant patients 
Based on available data, clinical manifestations of 
COVID-19 infection in pregnant women are similar 
to non-pregnant patients and fever, cough and 
dyspnea are the most prevalent complaints of these 
patients (1, 13, 42-45). The clinical spectrum of this 
disease ranges from asymptomatic infection to 
severe pneumonia and ARDS with multiple organ 
failure (42). Physiologic changes in cardiovascular, 
respiratory and immune systems during pregnancy 
increase the susceptibility of pregnant women to 
severe infection, which consequently leads to 
hypoxic insult in the fetus. Dominance of T helper 2 
(Th2) lymphocyte is an explanation for 
vulnerability of pregnant women to intracellular 
pathogens. In pregnant women infected with 
COVID-19, anti-inflammatory cytokines (IL-4, IL-
10) that are generated by Th2 play an important 
role in modulating immune system activities and 
may counter the effect of inflammatory cytokines 
(IL-6, IL-12, INF γ), which could lead to a decline in 
the severity of infection in these patients in 
comparison to non-pregnant women (43, 44). In a 
study conducted by Liu et al. 46% of patients had 
preterm labor and 38% of them went to the 
operating room for cesarean section secondary to 
pregnancy related complications such as 
premature rupture of membrane and fetal distress. 
There was also one case of stillbirth. In the 
mentioned study, only one patient was admitted to 
ICU as a result of severe respiratory distress but 
was finally discharged in good clinical condition. 
Effects of COVID-19 infection on the fetus were 
miscarriage (2%), intrauterine growth retardation 
(10%) and preterm labor (38%) (45). Chen et al. 
showed that vertical transmission of COVID-19 
does not occur during pregnancy and labor. In this 
small study, they collected samples from amniotic 
fluid, placenta, umbilical cord and neonatal throat 
swab in the operating room and analyzed them for 
SARS-CoV2 virus. They also evaluate breast milk 
for virus. All results were negative (43). In another 
study on seven pregnant patients with COVID-19 
admitted to hospital for delivery, in one neonate, 
throat swab tested positive for SARS-CoV2 36 
hours after the delivery (1). Current data are against 
vertical transmission of COVID-19 (13, 43).          
 Elderly patients 
Old patients with COVID-19 infection need special 
attention, because these patients usually suffer 
from many comorbidities such as hypertension, 
diabetes, cardiovascular diseases and chronic 
pulmonary disease that makes them susceptible to 
progressive and fatal complications (9, 15, 46, 47). On 
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the other hand, old age is an independent risk 
factor of death and severe adverse events in 
COVID-19 infection (46, 47). Wang et al. evaluated 
339 patients (mean age: 71 years) with COVID-19 
and followed them for four weeks. They found that 
71% of patients had severe and critical forms of 
infection and finally, 19% of these patients died. In 
the general population, only 18.5% of patients 
experience severe or critical forms of the disease 
and fatality is significantly lower than old age 
groups. They also showed that in the elderly group, 
mortality rate rises with increase in age (46). In 
another study by Lian et al. on 788 proved COVID-
19 cases, mortality and disease severity were 
higher in patients with age ≥60 years in 
comparison those aged ≤60 years. 
Lymphocytopenia and lower rates of hemoglobin 
and albumin, and rise in AST, CRP, LDH and 
creatine phosphokinase (CPK) were significantly 
more prevalent in older ages (47).  
 Pediatric Patients 
Based on current data, the prevalence of COVID-19 
in children is lower than adults and the nature of 
the infection is milder in the pediatric population 
(48-50). COVID-19 has been reported in all pediatric 
age groups and the youngest patient was a 36-hour 
neonate in China (1, 51). The most prevalent 
symptoms are fever, cough and weakness, which 
are similar to adult patients. Some patients may be 
afebrile and some others may first present with 
gastrointestinal symptoms such as diarrhea, 
nausea and vomiting and abdominal pain without 
any respiratory symptoms on presentation (29, 51). 
In a study on 36 pediatric patients with COVID-19, 
Qiu et al. showed that all patients had mild or 
moderate form of the disease. Laboratory 
derangements such as decrease in lymphocytes 
and increase in CPK, pro-calcitonin and D-dimer 
were more common in moderate cases (48). 
 Immunosuppressed and cancer patients 
Pro-inflammatory reaction of the immune system 
and production of T cell-mediated inflammatory 
cytokines such as IL2, IL7, IL10, GSCF, IP10, MCP1, 
MIP1A and TNF ɑ plays a central role in most 
complications of COVID-19 infection, specially 
severe respiratory presentations (17, 42). Therefore, 
it is no surprise that patients under treatment with 
immunosuppressive agents including organ 
transplant patients may show milder and atypical 
forms of COVID-19 infection (52). In a study on 320 
rheumatoid arthritis patients, Monti et al. found 4 
confirmed case of COVID-19 and 5 patients with 
symptoms suggestive of the disease and followed 
them for 2 weeks. Only one of them required 
hospital admission and only developed the need for 
low dose oxygen (53). There is also a case report of 
COVID-19 infection in two heart transplant 
patients under immune suppressive therapy with 
final improvement of both of them (42). Zhang et al. 
reported 28 cancer patients infected with COVID-
19, all of which had a history of cancer therapy in 
the previous 2 weeks. 53.6% of these patients 
showed severe clinical manifestations and 
eventually, 28.6% died. ARDS, septic shock and 
myocardial infarction were the most prevalent 
complications. Severe clinical manifestations were 
significantly more prevalent in cancer patients who 
had undergone anti-cancer therapy in the previous 
14 days compared to cancer patients without this 
history (54).  
CONCLUSIONS 
In summary, although the most common 
presentations in COVID-19 patients are fever, non-
producing cough and dyspnea, a considerable 
number of patients may seek healthcare without 
these complains. Asymptomatic patients and 
patients with only gastrointestinal and neurologic 
symptoms remain a significant challenge for 
medical practitioners. Special groups of patients 
may need more attention. They may need special 
evaluation strategies and protocols due to the 
difference in presentation, clinical course, severity, 
and disease progression in these patients 
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